Discontinuation and non-publication rates of U.S. clinical trials for the pharmacologic treatment of type 2 diabetes mellitus: A cross-sectional analysis

Conner Howard; Nicholas B. Sajjadi; Samuel Shepard; Jourdan Waddell; Stacy M. Chronister; Matt Vassar; Micah Hartwell

doi:10.1016/j.diabet.2021.101317

Discontinuation and non-publication rates of U.S. clinical trials for the pharmacologic treatment of type 2 diabetes mellitus: A cross-sectional analysis

Conner Howard, Nicholas B. Sajjadi, Samuel Shepard, Jourdan Waddell, Stacy M. Chronister, Matt Vassar, Micah Hartwell

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	101317
Journal	Diabetes and Metabolism
Volume	48
Issue number	2
DOIs	https://doi.org/10.1016/j.diabet.2021.101317
State	Published - Mar 2022

Access to Document

10.1016/j.diabet.2021.101317

Cite this

@article{46a9d8061a644b3aa4461ba5704c08c6,

title = "Discontinuation and non-publication rates of U.S. clinical trials for the pharmacologic treatment of type 2 diabetes mellitus: A cross-sectional analysis",

author = "Conner Howard and Sajjadi, {Nicholas B.} and Samuel Shepard and Jourdan Waddell and Chronister, {Stacy M.} and Matt Vassar and Micah Hartwell",

note = "Funding Information: No financial or other sources of support were provided during the development of this protocol. Matt Vassar reports grant funding from the National Institutes of Health, the U.S. Office of Research Integrity, and Oklahoma Center for the Advancement of Science and Technology, all outside the present work. Micah Hartwell receives research support through the US Department of Justice. Stacy Chronister is a paid speaker for NovoNordisk products which has no conflicts of interest with present work. All other authors have no conflicts of interest to report.",

year = "2022",

month = mar,

doi = "10.1016/j.diabet.2021.101317",

language = "English",

volume = "48",

journal = "Diabetes and Metabolism",

issn = "1262-3636",

publisher = "Elsevier Masson s.r.l.",

number = "2",

}

TY - JOUR

T1 - Discontinuation and non-publication rates of U.S. clinical trials for the pharmacologic treatment of type 2 diabetes mellitus

T2 - A cross-sectional analysis

AU - Howard, Conner

AU - Sajjadi, Nicholas B.

AU - Shepard, Samuel

AU - Waddell, Jourdan

AU - Chronister, Stacy M.

AU - Vassar, Matt

AU - Hartwell, Micah

N1 - Funding Information: No financial or other sources of support were provided during the development of this protocol. Matt Vassar reports grant funding from the National Institutes of Health, the U.S. Office of Research Integrity, and Oklahoma Center for the Advancement of Science and Technology, all outside the present work. Micah Hartwell receives research support through the US Department of Justice. Stacy Chronister is a paid speaker for NovoNordisk products which has no conflicts of interest with present work. All other authors have no conflicts of interest to report.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85122109747&partnerID=8YFLogxK

U2 - 10.1016/j.diabet.2021.101317

DO - 10.1016/j.diabet.2021.101317

M3 - Letter

C2 - 34929380

AN - SCOPUS:85122109747

SN - 1262-3636

VL - 48

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

IS - 2

M1 - 101317

ER -

Discontinuation and non-publication rates of U.S. clinical trials for the pharmacologic treatment of type 2 diabetes mellitus: A cross-sectional analysis

Access to Document

Other files and links

Cite this